Further confusion arises from the Paradigm-HF trial (prospective comparison of angiotensin receptor neprilysin inhibitors [ARNI] with angiotensin converting enzyme inhibitors [ACEI] to determine the impact on global mortality and morbidity in HF) [34]. The gene discussed is ACE; the disease is hydrops fetalis.